Why Is Canada-Based Cannabis Firm Canopy Growth Stock Trading Lower On Friday?
1. Canopy Growth reported Q3 2025 sales of CA$74.76 million, beating expectations. 2. Medical cannabis revenue rose 16%, but adult-use revenue fell by 10%. 3. Storz & Bickel saw a 19% revenue increase driven by holiday sales. 4. Adjusted EBITDA loss improved to CA$3 million due to cost savings. 5. Gross margin decreased by 400 basis points to 32% amid increased costs.